Spontaneous Reporting Systems (SRS) are a cornerstone of post-marketing drug safety surveillance. Healthcare professionals and patients voluntarily submit reports of suspected adverse drug reactions (ADRs) to a central database. While subject to under-reporting and bias, these systems are crucial for detecting rare, unexpected, or long-latency ADRs that may not be identified during pre-market clinical trials.
